Replication-competent influenza B reporter viruses as tools for screening antivirals and antibodies

Journal of Virology

Volumn 89, Issue 23, 2015, Pages 12226-12231

  Fulton, Benjamin O ^a   Palese, Peter ^a   Heaton, Nicholas S ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NEUTRALIZING ANTIBODY; ZANAMIVIR; PHOTOPROTEIN;

ANTIBODY DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; BIOASSAY; BIOLUMINESCENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; INFLUENZA B VIRUS; MICRONEUTRALIZATION ASSAY; MICROSCOPY; NONHUMAN; PLAQUE REDUCTION ASSAY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUALITY CONTROL; SENSITIVITY ANALYSIS; VIROGENESIS; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; DOG; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETICS; MDCK CELL LINE; METABOLISM; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; REPORTER GENE;

ANIMALS; DOGS; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; GENES, REPORTER; INFLUENZA B VIRUS; LUMINESCENT PROTEINS; MADIN DARBY CANINE KIDNEY CELLS; MICROSCOPY, FLUORESCENCE; VIRUS REPLICATION;

EID: 84949638376     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02164-15     Document Type: Article

References (32)

1. Vijaykrishna D, Holmes EC, Joseph U, Fourment M, Su YC, Halpin R, Lee RT, Deng YM, Gunalan V, Lin X, Stockwell TB, Fedorova NB, Zhou B, Spirason N, Kuhnert D, Boskova V, Stadler T, Costa AM, Dwyer DE, Huang QS, Jennings LC, Rawlinson W, Sullivan SG, Hurt AC, Maurer-Stroh S, Wentworth DE, Smith GJ, Barr IG. 2015. The contrasting phylodynamics of human influenza B viruses. eLife 4:e05055. http://dx.doi.org/10.7554/eLife.05055.
2. Belshe RB. 2010. The need for quadrivalent vaccine against seasonal influenza. Vaccine 28(Suppl 4):D45-D53. http://dx.doi.org/10.1016/j.vaccine.2010.08.028.
3. Chen R, Holmes EC. 2008. The evolutionary dynamics of human influenza B virus. J Mol Evol 66:655-663. http://dx.doi.org/10.1007/s00239-008-9119-z.
4. Palese P, Shaw ML. 2013. Orthomyxoviridae: the viruses and their replication, 6th ed. Wolters Kluwer/Lippincott Williams & Wilkins Health, Philadelphia, PA.
5. Fiege JK, Langlois RA. 2015. Investigating influenza A virus infection: tools to track infection and limit tropism. J Virol 89:6167-6170. http://dx.doi.org/10.1128/JVI.00462-15.
6. Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, Garcia-Sastre A. 2010. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A 107: 11531-11536. http://dx.doi.org/10.1073/pnas.0914994107.
7. Heaton NS, Leyva-Grado VH, Tan GS, Eggink D, Hai R, Palese P. 2013. In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies. J Virol 87: 8272-8281. http://dx.doi.org/10.1128/JVI.00969-13.
8. Tran V, Moser LA, Poole DS, Mehle A. 2013. Highly sensitive real-time in vivo imaging of an influenza reporter virus reveals dynamics of replication and spread. J Virol 87:13321-13329. http://dx.doi.org/10.1128/JVI.02381-13.
9. Karlsson EA, Meliopoulos VA, Savage C, Livingston B, Mehle A, Schultz-Cherry S. 2015. Visualizing real-time influenza virus infection, transmission and protection in ferrets. NatCommun6:6378. http://dx.doi.org/10.1038/ncomms7378.
10. Pan W, Dong Z, Li F, Meng W, Feng L, Niu X, Li C, Luo Q, Li Z, Sun C, Chen L. 2013. Visualizing influenza virus infection in living mice. Nat Commun 4:2369. http://dx.doi.org/10.1038/ncomms3369.
11. Pena L, Sutton T, Chockalingam A, Kumar S, Angel M, Shao H, Chen H, Li W, Perez DR. 2013. Influenza viruses with rearranged genomes as live-attenuated vaccines. J Virol 87:5118-5127. http://dx.doi.org/10.1128/JVI.02490-12.
12. Sutton TC, Obadan A, Lavigne J, Chen H, Li W, Perez DR. 2014. Genome rearrangement of influenza virus for anti-viral drug screening. Virus Res 189:14-23. http://dx.doi.org/10.1016/j.virusres.2014.05.003.
13. Heaton NS, Langlois RA, Sachs D, Lim JK, Palese P, tenOever BR. 2014. Long-term survival of influenza virus infected club cells drives immunopathology. J Exp Med 211:1707-1714. http://dx.doi.org/10.1084/jem.20140488.
14. Eckert N, Wrensch F, Gartner S, Palanisamy N, Goedecke U, Jager N, Pohlmann S, Winkler M. 2014. Influenza A virus encoding secreted Gaussia luciferase as useful tool to analyze viral replication and its inhibition by antiviral compounds and cellular proteins. PLoS One 9:e97695. http://dx.doi.org/10.1371/journal.pone.0097695.
15. Fukuyama S, Katsura H, Zhao D, Ozawa M, Ando T, Shoemaker JE, Ishikawa I, Yamada S, Neumann G, Watanabe S, Kitano H, Kawaoka Y. 2015. Multi-spectral fluorescent reporter influenza viruses (Color-flu) as powerful tools for in vivo studies. Nat Commun 6:6600. http://dx.doi.org/10.1038/ncomms7600.
16. Spronken MI, Short KR, Herfst S, Bestebroer TM, Vaes VP, van der Hoeven B, Koster AJ, Kremers GJ, Scott DP, Gultyaev AP, Sorell EM, de Graaf M, Barcena M, Rimmelzwaan GF, Fouchier RA. 2015. Optimisations and challenges involved in the creation of various bioluminescent and fluorescent influenza A virus strains for in vitro and in vivo applications. PLoS One 10:e0133888. http://dx.doi.org/10.1371/journal.pone.0133888.
17. Reuther P, Gopfert K, Dudek AH, Heiner M, Herold S, Schwemmle M. 2015. Generation of a variety of stable influenza A reporter viruses by genetic engineering of the NS gene segment. Sci Rep 5:11346. http://dx.doi.org/10.1038/srep11346.
18. Beyleveld G, White KM, Ayllon J, Shaw ML. 2013. New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions. Antiviral Res 100:120-132. http://dx.doi.org/10.1016/j.antiviral.2013.07.018.
19. Konig R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, Garcia-Sastre A, Young JA, Palese P, Shaw ML, Chanda SK. 2010. Human host factors required for influenza virus replication. Nature 463:813-817. http://dx.doi.org/10.1038/nature08699.
20. Kim JH, Lee SR, Li LH, Park HJ, Park JH, Lee KY, Kim MK, Shin BA, Choi SY. 2011. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 6:e18556. http://dx.doi.org/10.1371/journal.pone.0018556.
21. Shaner NC, Lambert GG, Chammas A, Ni Y, Cranfill PJ, Baird MA, Sell BR, Allen JR, Day RN, Israelsson M, Davidson MW, Wang J. 2013. A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum. Nat Methods 10:407-409. http://dx.doi.org/10.1038/nmeth.2413.
22. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. 1999. Rescue of influenza A virus from recombinant DNA. J Virol 73:9679-9682.
23. Martinez-Sobrido L, Garcia-Sastre A. 3 August 2010. Generation of recombinant influenza virus from plasmid DNA. J Vis Exp http://dx.doi.org/10.3791/2057.
24. Hai R, Martinez-Sobrido L, Fraser KA, Ayllon J, Garcia-Sastre A, Palese P. 2008. Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol 82:10580-10590. http://dx.doi.org/10.1128/JVI.01213-08.
25. Bouvier NM, Lowen AC, Palese P. 2008. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol 82:10052-10058. http://dx.doi.org/10.1128/JVI.01226-08.
26. Burnham AJ, Armstrong J, Lowen AC, Webster RG, Govorkova EA. 2015. Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium. J Virol 89:4575-4587. http://dx.doi.org/10.1128/JVI.02473-14.
27. FDA. 2014. FDA approves Rapivab to treat flu infection. FDA, Silver Spring, MD. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm. Accessed 7 August 2015.
28. 274Y. Antimicrob Agents Chemother 58:2718-2730. http://dx.doi.org/10.1128/AAC.02628-13.
29. Farrukee R, Mosse J, Hurt AC. 2013. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. Expert Rev Anti Infect Ther 11:1135-1145. http://dx.doi.org/10.1586/14787210.2013.842466.
30. Burnham AJ, Baranovich T, Govorkova EA. 2013. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res 100:520-534. http://dx.doi.org/10.1016/j.antiviral.2013.08.023.
31. Barnett JM, Cadman A, Gor D, Dempsey M, Walters M, Candlin A, Tisdale M, Morley PJ, Owens IJ, Fenton RJ, Lewis AP, Claas EC, Rimmelzwaan GF, De Groot R, Osterhaus AD. 2000. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 44:78-87. http://dx.doi.org/10.1128/AAC.44.1.78-87.2000.
32. Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. 2014. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol 88:13260-13268. http://dx.doi.org/10.1128/JVI.02133-14.